AlphAIAlphAI — Financial news for AI agents
Zacks CommentaryMAY 194 min read$CGEN

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

Compugen (CGEN) delivered earnings and revenue surprises of -33.33% and 38.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published May 19, 2025, 3:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 20, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates — source image
Source · www.zacks.com
Decision brief

The 30-second read

$CGENNeutralLow
01

Why it matters

Earnings miss may lead to short-term price declines; revenue growth suggests potential for future recovery.

02

Market read

The news is highly relevant for traders focusing on biotech stocks, especially CGEN, with potential short-term volatility.

03

What to watch

Broader market trends and upcoming catalysts could influence stock movement beyond earnings results.

Timing: short-term (next few days)

Background

Compugen is a biotech company reporting Q1 2025 earnings, with notable revenue growth but significant earnings miss.

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

The news directly pertains to Compugen's recent quarterly earnings report, making it highly relevant for short-term trading decisions.

Expected impact

Potential short-term decline followed by stabilization or slight rebound as investors digest the mixed results.

Evidence & confidence

Earnings misses typically exert downward pressure, but strong revenue growth can mitigate negative sentiment. The net effect depends on investor perception and broader market conditions.

Market effects

Sector

Potential cautiousness in biotech and life sciences sectors due to earnings volatility.

Regional

Limited regional impact; primarily affects US-based biotech stocks.

Global

Minimal; specific to US biotech sector.

Counterpoint

What could challenge this read

The revenue beat indicates underlying strength; the stock may rebound after initial sell-off.

Key entities

  • Company
    Compugen Ltd.

    Biotech firm focused on immuno-oncology and other therapeutic areas.

Read at source← All news

Related articles

AUG 3
$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

prnewswire.com7 min
SEP 17
$DASHMed

DoorDash and Uber eats nationwide delivery services from Costco

Costco partners with DoorDash for nationwide U.S. delivery, expanding from select international markets. Only Costco members linking accounts can use the service. Costco has 81M members and 639 U.S. stores. Instacart has offered delivery for about a decade. Earlier in 2024, Costco also partnered with Uber Eats, which has since expanded nationwide.

sjvsun.com2 min
SEP 17
$LMTMed

LMT Looks 4.5% Undervalued on GF Value™ with Strong Dividend App

Lockheed Martin (LMT) secured a $234.46M contract modification for 16 UH-60M Black Hawk helicopters, raising the total contract value to $356.25M. The company offers a 2.55% dividend yield, a 50% payout ratio, and a 3-year dividend growth rate of 5.4%. LMT's GF Score™ is 80/100, with strengths in profitability and valuation. Institutional activity shows mixed sentiment, with 21 premium gurus holding shares. The stock is trading 4.5% below its GF Value™ of $563.60, at $538.09.

gurufocus.com2 min
SEP 17
$UBERLow

Uber Technologies sells $182.2m of Aurora Innovation stock

Uber sold 29.4 million shares of Aurora Innovation (AUR) for $182.2 million at $6.205 per share, reducing its stake to 157.1 million shares. Aurora's Q2 2026 earnings showed a wider-than-expected loss of $0.14 per share but higher revenue of $2 million. The stock has surged 54% in six months, though it may be overvalued according to InvestingPro analysis.

investing.com2 min